<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042691</url>
  </required_header>
  <id_info>
    <org_study_id>02-135</org_study_id>
    <nct_id>NCT01042691</nct_id>
  </id_info>
  <brief_title>Isolated Liver Perfusion With Oxaliplatin</brief_title>
  <official_title>A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Bartlett</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Pittsburgh Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this research study is to determine a safe dose for the drug oxaliplatin
      when delivered by isolated hepatic perfusion. The second goal of this research study is to
      determine if isolated hepatic perfusion with oxaliplatin can improve the efficacy of standard
      hepatic arterial infusional (HAI) therapy with floxuridine (FUDR)/leucovorin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose and dose limiting toxicity of oxaliplatin delivered via isolated hepatic perfusion (IHP).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if isolated hepatic perfusion with oxaliplatin can increase the response rate, duration of response and survival of patients being treated with standard HAI with FUDR when compared to historical controls.</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the tissue absorption of oxaliplatin in normal liver versus tumor during IHP.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Unresectable Colorectal Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be included that are scheduled to undergo surgery for placement of
             hepatic arterial infusion pump for HAI therapy and

          -  Histologically or cytologically proven measurable metastatic colorectal cancer limited
             to the parenchyma of the liver with no evidence of unresectable extrahepatic disease
             by preoperative radiological studies. Limited resectable extrahepatic disease is
             acceptable.

          -  No chemotherapy, radiotherapy, or biologic therapy for their malignancy in the 4 weeks
             prior to the liver perfusion and must have recovered from all side effects.

          -  An ECOG performance standard of 0, 1 or 2 for 24 hours prior to surgery.

          -  Adequate hepatic function as evidenced by bilirubin &lt; 2.0 mg/dL and a PT &lt; 2 seconds
             greater than the upper limit of normal.

          -  Age equal to 18 years or older and greater than 30 kg.

          -  Platelet counts greater than 100,000, a hematocrit &gt; 27.0, a white blood count &gt;
             3000/microliter, and a creatinine less than or equal to 1.5 mg/dL or a creatinine
             clearance of &gt; 60 mL/min. Patients with elevations in hepatic transaminases secondary
             to the presence of metastatic disease in the liver are eligible.

          -  Aware of the neoplastic nature of his/her illness, the experimental nature of the
             therapy, alternative treatments, potential benefits, and risks and willing to sign an
             informed consent.

          -  The disease in the liver must be considered unresectable as defined by greater than
             three sites of disease in the liver, bilobar disease, and tumor abutting major
             vascular or ductal structures making anatomic resection with preservation of liver
             function impossible.

        Exclusion Criteria:

          -  Pregnant patients and nursing mothers will be excluded due to the unknown effects of
             oxaliplatin on the fetus or newborn

          -  Patients taking immunosuppressive drugs or on chronic anticoagulation will not be
             eligible.

          -  Patients with active infections are not eligible.

          -  Patients with biopsy proven cirrhosis or evidence of significant portal hypertension
             manifested by ascites, esophageal varices on endoscopy, or radiologic studies showing
             significant collateral vessels around the organs drained by the portal venous system
             will be excluded.

          -  Patients with ischemic cardiac disease or history of congestive heart failure with an
             LVEF &lt; 40% will be excluded.

          -  Patients with COPD or other chronic pulmonary disease with PFT's indicating an FEV&lt;
             50% predicted for age will be excluded.

          -  Patients with a history of veno-occlusive disease of the liver are ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L Bartlett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers, Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lahr CJ, Soong SJ, Cloud G, Smith JW, Urist MM, Balch CM. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol. 1983 Nov;1(11):720-6.</citation>
    <PMID>6668490</PMID>
  </reference>
  <reference>
    <citation>Blumgart LH, Fong Y. Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg. 1995 May;32(5):333-421. Review.</citation>
    <PMID>7538062</PMID>
  </reference>
  <reference>
    <citation>Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transpl Surg. 1999 Jan;5(1):65-80. Review.</citation>
    <PMID>9873095</PMID>
  </reference>
  <reference>
    <citation>Bartlett DL. Treatment of patients with hepatic metastases. Cancer J. 2000 Apr;6 Suppl 2:S169-76. Review.</citation>
    <PMID>10803832</PMID>
  </reference>
  <reference>
    <citation>Balch CM, Urist MM, Soong SJ, McGregor M. A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg. 1983 Nov;198(5):567-73.</citation>
    <PMID>6227295</PMID>
  </reference>
  <reference>
    <citation>Kemeny,M.M., S.Adak, and S.Lipsitz. 1999. Results of the intergroup [Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG) prospective randomized study of surgery alone versus continuous hepatic artery infusion of FuDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases. Proc ASCO 18:1012.</citation>
  </reference>
  <reference>
    <citation>Lokich JJ, Sonneborn H, Paul S, Zipoli T. Phase I study of continuous venous infusion of floxuridine (5-FUDR) chemotherapy. Cancer Treat Rep. 1983 Sep;67(9):791-3.</citation>
    <PMID>6224555</PMID>
  </reference>
  <reference>
    <citation>Alexander HR Jr, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol. 1996 Nov-Dec;12(6):416-28. Review.</citation>
    <PMID>8914206</PMID>
  </reference>
  <reference>
    <citation>Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998 Apr;16(4):1479-89.</citation>
    <PMID>9552055</PMID>
  </reference>
  <reference>
    <citation>Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001 Feb;129(2):176-87.</citation>
    <PMID>11174711</PMID>
  </reference>
  <reference>
    <citation>Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. Review.</citation>
    <PMID>9834817</PMID>
  </reference>
  <reference>
    <citation>Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996 Dec 24;52(12):1855-65.</citation>
    <PMID>8951344</PMID>
  </reference>
  <reference>
    <citation>Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, Goecke E, Waggershauser T, Braess J, Schalhorn A, Hiddemann W. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001 May;12(5):599-603.</citation>
    <PMID>11432616</PMID>
  </reference>
  <reference>
    <citation>Rietbroek RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, Veenhof CH. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol. 1997;123(1):6-12.</citation>
    <PMID>8996534</PMID>
  </reference>
  <reference>
    <citation>Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia. 2002 Jul-Aug;18(4):307-15.</citation>
    <PMID>12079586</PMID>
  </reference>
  <reference>
    <citation>Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002 Feb;13(2):267-72.</citation>
    <PMID>11886004</PMID>
  </reference>
  <reference>
    <citation>Alexander,H.R., D.L.Bartlett, D.L.Fraker, S.K.Libutti, T.Moser, and S.A.Rosenberg. 1997. Results of a Phase II study of isolated hepatic perfusion (IHP) with tumor necrosis factor (TNF) and melphalan for unresectable primary or metastatic cancer confined to the liver. Proc.Soc.Surg.Oncol. 6:8. (Abstr.)</citation>
  </reference>
  <reference>
    <citation>Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000 Aug;6(8):3062-70.</citation>
    <PMID>10955785</PMID>
  </reference>
  <reference>
    <citation>Erkmen K, Egorin MJ, Reyno LM, Morgan R Jr, Doroshow JH. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol. 1995;35(3):254-6.</citation>
    <PMID>7805185</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>David Bartlett</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

